China CAS:1778-02-5 Manufacturer

Sticking to the principle of "Super Good quality, Satisfactory service" ,We are striving to become an excellent organization partner of you for CAS:1778-02-5,Pregnenolone, Our goal is always to enable clients comprehend their plans. We have been creating good endeavours to accomplish this win-win scenario and sincerely welcome you to join us.
CAS:1778-02-5, We severely promise that we give all the customers with the best quality products and solutions, the most competitive prices and the most prompt delivery. We hope to win a resplendent future for customers and ourselves.

Hot Products

  • Eslicarbazepine Acetate

    Eslicarbazepine Acetate

    Eslicarbazepine Acetate has In-house specification. DMF approved.

    CAS:236395-14-5

  • Cbz-Valganciclovir

    Cbz-Valganciclovir

    Cbz-Valganciclovir,N-Carbobenzyloxy-L-valinyl-ganciclovir (cas# 194154-40-0) is a compound useful in organic synthesis.

    CAS:194154-40-0

  • Lasmiditan Succinate

    Lasmiditan Succinate

    Lasmiditan Succinate has In-house specification. DMF approved.

    CAS:439239-92-6

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive
  • Epiandrosterone

    Epiandrosterone

    Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).

    CAS:481-29-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept